We further show that galunisertib treatment inhibits TGFβ1-driven EMT and migration of tumor cells, reverses TGFβ1-mediated immune suppression, and inhibits in vivo growth of human tumor xenografts and syngenic murine tumors. This evidence concerns the gene TGFB1 and neoplasm.